Elisa Espinet

Elisa Espinet


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2020 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
EEElisa Espinet
Elisa Espinet
ZGZuguang Gu
Zuguang Gu
CICharles D. Imbusch
Charles D. Imbusch
NGNathalia A. Giese
Nathalia A. Giese
MBMagdalena Büscher
Magdalena Büscher
ATAndreas Trumpp
Andreas Trumpp
Pancreatic ductal adenocarcinoma (PDAC) is characterized by extensive desmoplasia, which challenges the molecular analyses of bulk tumor samples. Here we FACS-purified epithelial cells from human PDAC and normal pancreas and derived their genome-wide transcriptome and DNA methylome landscapes. Clustering based on DNA methylation revealed two distinct PDAC groups displaying different methylation patterns at regions encoding repeat elements. Methylationlow tumors are characterized by higher expression of endogenous retroviral transcripts and double-stranded RNA sensors, which lead to a cell-intrinsic activation of an interferon signature (IFNsign). This results in a protumorigenic microenvironment and poor patient outcome. Methylationlow/IFNsignhigh and Methylationhigh/IFNsignlow PDAC cells preserve lineage traits, respective of normal ductal or acinar pancreatic cells. Moreover, ductal-derived KrasG12D/Trp53−/− mouse PDACs show higher expression of IFNsign compared with acinar-derived counterparts. Collectively, our data point to two different origins and etiologies of human PDACs, with the aggressive Methylationlow/IFNsignhigh subtype potentially targetable by agents blocking intrinsic IFN signaling. Significance: The mutational landscapes of PDAC alone cannot explain the observed interpatient heterogeneity. We identified two PDAC subtypes characterized by differential DNA methylation, preserving traits from normal ductal/acinar cells associated with IFN signaling. Our work suggests that epigenetic traits and the cell of origin contribute to PDAC heterogeneity. This article is highlighted in the In This Issue feature, p. 521

15 November 2021 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
MTMengyu Tu
Mengyu Tu
LKLukas Klein
Lukas Klein
EEElisa Espinet
Elisa Espinet
TGTheodoros Georgomanolis
Theodoros Georgomanolis
FWFlorian Wegwitz
Florian Wegwitz
SSShiv Singh
Shiv Singh

12 July 2023 in EMBO Molecular Medicine
Verified
Journal Article
Open access
HAHamed Alborzinia
Hamed Alborzinia
ZCZhiyi Chen
Zhiyi Chen
UYUmut Yildiz
Umut Yildiz
FFFlorencio Porto Freitas
Florencio Porto Freitas
FVFelix C E Vogel
Felix C E Vogel
JAJosé Pedro Friedmann Angeli
José Pedro Friedmann Angeli
Ferroptosis has emerged as an attractive strategy in cancer therapy. Understanding the operational networks regulating ferroptosis may unravel vulnerabilities that could be harnessed for therapeutic benefit. Using CRISPR‐activation screens in ferroptosis hypersensitive cells, we identify the selenoprotein P (SELENOP) receptor, LRP8, as a key determinant protecting MYCN ‐amplified neuroblastoma cells from ferroptosis. Genetic deletion of LRP8 leads to ferroptosis as a result of an insufficient supply of selenocysteine, which is required for the translation of the antiferroptotic selenoprotein GPX4. This dependency is caused by low expression of alternative selenium uptake pathways such as system Xc − . The identification of LRP8 as a specific vulnerability of MYCN ‐amplified neuroblastoma cells was confirmed in constitutive and inducible LRP8 knockout orthotopic xenografts. These findings disclose a yet‐unaccounted mechanism of selective ferroptosis induction that might be explored as a therapeutic strategy for high‐risk neuroblastoma and potentially other MYCN ‐amplified entities.

1 September 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
MSMahak Singhal
Mahak Singhal
NGNicolas Gengenbacher
Nicolas Gengenbacher
APAshik Ahmed Abdul Pari
Ashik Ahmed Abdul Pari
MKMiki Kamiyama
Miki Kamiyama
LHLing Hai
Ling Hai
HAHellmut Augustin
Hellmut Augustin
A temporal systems biology screen of premetastatic endothelial cells identified LRG1 as a therapeutic target for restricting metastases.

24 April 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
LWLena Wiedmann
Lena Wiedmann
FRFrancesca De Angelis Rigotti
Francesca De Angelis Rigotti
NVNuria Vaquero-Siguero
Nuria Vaquero-Siguero
EDElisa Donato
Elisa Donato
EEElisa Espinet
Elisa Espinet
Juan Rodriguez VitaJuan Rodriguez Vita
Juan Rodriguez Vita
Pancreatic ductal adenocarcinoma (PDAC) frequently metastasizes into the peritoneum, which contributes to poor prognosis. Metastatic spreading is promoted by cancer cell plasticity, yet its regulation by the microenvironment is incompletely understood. Here, we show that the presence of hyaluronan and proteoglycan link protein-1 (HAPLN1) in the extracellular matrix enhances tumor cell plasticity and PDAC metastasis. Bioinformatic analysis showed that HAPLN1 expression is enriched in the basal PDAC subtype and associated with worse overall patient survival. In a mouse model for peritoneal carcinomatosis, HAPLN1-induced immunomodulation favors a more permissive microenvironment, which accelerates the peritoneal spread of tumor cells. Mechanistically, HAPLN1, via upregulation of tumor necrosis factor receptor 2 (TNFR2), promotes TNF-mediated upregulation of Hyaluronan (HA) production, facilitating EMT, stemness, invasion and immunomodulation. Extracellular HAPLN1 modifies cancer cells and fibroblasts, rendering them more immunomodulatory. As such, we identify HAPLN1 as a prognostic marker and as a driver for peritoneal metastasis in PDAC.

9 August 2022 in Gut
Verified
Journal Article
Open access
PDF file
SLSven-Thorsten Liffers
Sven-Thorsten Liffers
LGLaura Godfrey
Laura Godfrey
LFLisa Frohn
Lisa Frohn
LHLena Haeberle
Lena Haeberle
AYAslihan Yavas
Aslihan Yavas
Irene EspositoIrene Esposito
Irene Esposito
Objective Due to the limited number of modifiable risk factors, secondary prevention strategies based on early diagnosis represent the preferred route to improve the prognosis of pancreatic ductal adenocarcinoma (PDAC). Here, we provide a comparative morphogenetic analysis of PDAC precursors aiming at dissecting the process of carcinogenesis and tackling the heterogeneity of preinvasive lesions. Design Targeted and whole-genome low-coverage sequencing, genome-wide methylation and transcriptome analyses were applied on a final collective of 122 morphologically well-characterised low-grade and high-grade PDAC precursors, including intestinal and gastric intraductal papillary mucinous neoplasms (IPMN) and pancreatic intraepithelial neoplasias (PanIN). Results Epigenetic regulation of mucin genes determines the phenotype of PDAC precursors. PanIN and gastric IPMN display a ductal molecular profile and numerous similarly regulated pathways, including the Notch pathway, but can be distinguished by recurrent deletions and differential methylation and, in part, by the expression of mucin-like 3. Intestinal IPMN are clearly distinct lesions at the molecular level with a more instable genotype and are possibly related to a different ductal cell compartment. Conclusions PDAC precursors with gastric and intestinal phenotype are heterogeneous in terms of morphology, genetic and epigenetic profile. This heterogeneity is related to a different cell identity and, possibly, to a different aetiology.